Raymond EVERS   SITE

  • Drug Metab Dispos. 2020;48:1147-1160. A two-tiered in vitro approach to de-risk drug candidates for potential bile salt export pump inhibition liabilities in drug discovery. Hafey MJ, Houle R, Tanis KQ, Knemeyer I, Shang J, Chen Q, Baudy A, Monroe J, Sistare FD, Evers R. PubMed
  • Clin Pharmacol Ther. 2020;In press. A microdose cocktail to evaluate drug interactions in patients with renal impairment. Tatosian DA, Yee KL, Zhang Z, Mostoller K, Paul E, Sutradhar S, Larson P, Chhibber A, Wen J, Wang YJ, Lassman M, Latham AH, Pang J, Crumley T, Gillespie A, Marricco NC, Marenco T, Murphy M, Lasseter KC, Marbury TC, Tweedie D, Chu X, Evers R, Stoch SA. PubMed
  • Toxicol Sci. 2019;2019;170:180-198. Use of a Bile Salt Export Pump knockdown rat susceptibility model to interrogate mechanism of drug induced liver toxicity. Li Y, Evers R, Hafey MJ, Cheon K, Duong H, Lynch D, LaFranco-Scheuch L, Pacchione S, Tamburino A, Tanis K, Geddes K, Holder D, Rena Zhang N, Kang W, Gonzalez RJ, Galijatovic-Idrizbegovic A, Pearson K, Lebron J, Glaab WE, Sistare FD. PubMed
  • Clin Pharmacol Ther. 2019;106:228-237.  Interindividual and regional variability in drug transporter abundance at the human blood-brain barrier measured by quantitative targeted proteomics. Billington S, Salphati L, Hop CECA, Chu X, Evers R, Burdette D, Rowbottom C, Lai Y, Xiao G, Humphreys WG, Nguyen TB, Prasad B, Unadkat JD. PubMed
  • Clin Pharmacol Ther. 2018;104:900-915. Disease-associated changes in drug transporters may impact the pharmacokinetics and/or toxicity of drugs: a white paper from the International Transporter Consortium. Evers R, Piquette-Miller M, Polli JW, Russel FGM, Sprowl JA, Tohyama K, Ware JA, de Wildt SN, Xie W, Brouwer KLR; International Transporter Consortium. PubMed
  • Drug Metab Dispos. 2018;46:189-196. Transporter expression in noncancerous and cancerous liver tissue from donors with hepatocellular carcinoma and chronic hepatitis C infection quantified by LC-MS/MS proteomics. Billington S, Ray AS, Salphati L, Xiao G, Chu X, Humphreys WG, Liao M, Lee CA, Mathias A, Hop CECA, Rowbottom C, Evers R, Lai Y, Kelly EJ, Prasad B, Unadkat JD. PubMed
  • J Pharm Sci. 2017;106:2357-2367. Identification of endogenous biomarkers to predict the propensity of drug candidates to cause hepatic or renal transporter-mediated drug-drug interactions. Chu X, Chan GH, Evers R. PubMed
  • Toxicol Sci. 2017;157:30-40. Antibiotic-induced elevations of plasma bile acids in rats independent of Bsep inhibition. Li Y, Hafey MJ, Duong H, Evers R, Cheon K, Holder DJ, Galijatovic-Idrizbegovic A, Sistare FD, Glaab WE. PubMed
  • Clin Pharmacol Ther. 2017;101:519-530. Validation of a microdose probe drug cocktail for clinical drug interaction assessments for drug transporters and CYP3A. Prueksaritanont T, Tatosian DA, Chu X, Railkar R, Evers R, Chavez-Eng C, Lutz R, Zeng W, Yabut J, Chan GH, Cai X, Latham AH, Hehman J, Stypinski D, Brejda J, Zhou C, Thornton B, Bateman KP, Fraser I, Stoch SA. PubMed
  • Drug Metab Dispos. 2016;44:1752-1758. Transporter expression in liver tissue from subjects with alcoholic or hepatitis C cirrhosis quantified by targeted quantitative proteomics. Wang L, Collins C, Kelly EJ, Chu X, Ray AS, Salphati L, Xiao G, Lee C, Lai Y, Liao M, Mathias A, Evers R, Humphreys W, Hop CE, Kumer SC, Unadkat JD. PubMed
  • Clin Pharmacol Ther. 2016;100:437-440. Transporters affecting biochemical test results: Creatinine-drug interactions. Chu X, Bleasby K, Chan GH, Nunes I, Evers R. PubMed
  • Clin Pharmacol Ther. 2016;100:362-70. Ontogeny of hepatic drug transporters as quantified by LC-MS/MS proteomics. Prasad B, Gaedigk A, Vrana M, Gaedigk R, Leeder JS, Salphati L, Chu X, Xiao G, Hop C, Evers R, Gan L, Unadkat JD. PubMed
  • Pharmacogenomics. 2016;17:615-31. Assessment of drug metabolism enzyme and transporter pharmacogenetics in drug discovery and early development: perspectives of the I-PWG. Brian W, Tremaine LM, Arefayene M, de Kanter R, Evers R, Guo Y, Kalabus J, Lin W, Loi CM, Xiao G. PubMed 
  • Drug Metab Dispos. 2016;44:1498-509. The complexities of interpreting reversible elevated serum Creatinine levels in drug development: does a correlation with inhibition of renal transporters exist? Chu X, Bleasby K, Chan GH, Nunes I, Evers R. PubMed
  • Drug Metab Dispos. 2015;43:851-63. Evaluation of cynomolgus monkeys for the identification of endogenous biomarkers for hepatic transporter inhibition and as a translatable model to predict pharmacokinetic interactions with statins in humans. Chu X, Shih SJ, Shaw R, Hentze H, Chan GH, Owens K, Wang S, Cai X, Newton D, Castro-Perez J, Salituro G, Palamanda J, Fernandis A, Ng CK, Liaw A, Savage MJ, Evers R. PubMed
  • Drug Metab Dispos. 2015;43:774-85. Establishment of a hepatocyte-kupffer cell coculture model for assessment of proinflammatory cytokine effects on metabolizing enzymes and drug transporters. Nguyen TV, Ukairo O, Khetani SR, McVay M, Kanchagar C, Seghezzi W, Ayanoglu G, Irrechukwu O, Evers R. PubMed
  • Drug Metab Dispos. 2015;43:367-74. Interspecies variability in expression of hepatobiliary transporters across human, dog, monkey, and rat as determined by quantitative proteomics. Wang L, Prasad B, Salphati L, Chu X, Gupta A, Hop CE, Evers R, Unadkat JD. PubMed
  • Drug Metab Dispos. 2015;43:284-8. Quantitative transporter proteomics by liquid chromatography with tandem mass spectrometry: addressing methodologic issues of plasma membrane isolation and expression-activity relationship. Kumar V, Prasad B, Patilea G, Gupta A, Salphati L, Evers R, Hop CE, Unadkat JD. PubMed
  • Drug Metab Dispos. 2014;42:1301-13. Evaluation of organic anion transporting polypeptide 1B1 and 1B3 humanized mice as a translational model to study the pharmacokinetics of statins. Salphati L, Chu X, Chen L, Prasad B, Dallas S, Evers R, Mamaril-Fishman D, Geier EG, Kehler J, Kunta J, Mezler M, Laplanche L, Pang J, Rode A, Soars MG, Unadkat JD, van Waterschoot RA, Yabut J, Schinkel AH, Scheer N. PubMed
  • Br J Clin Pharmacol. 2014;78:587-98. Pitavastatin is a more sensitive and selective organic anion-transporting polypeptide 1B clinical probe than rosuvastatin. Prueksaritanont T, Chu X, Evers R, Klopfer SO, Caro L, Kothare PA, Dempsey C, Rasmussen S, Houle R, Chan G, Cai X, Valesky R, Fraser IP, Stoch SA. PubMed
  • Drug Metab Dispos. 2014;42:78-88. Interindividual variability in hepatic organic anion-transporting polypeptides and P-glycoprotein (ABCB1) protein expression: quantification by liquid chromatography tandem mass spectroscopy and influence of genotype, age, and sex. Prasad B, Evers R, Gupta A, Hop CE, Salphati L, Shukla S, Ambudkar SV, Unadkat JD. PubMed
  • Clin Pharmacol Ther. 2013;94:95-112. In vitro methods to support transporter evaluation in drug discovery and development. Brouwer KL, Keppler D, Hoffmaster KA, Bow DA, Cheng Y, Lai Y, Palm JE, Stieger B, Evers R; International Transporter Consortium. PubMed
  • Drug Metab Dispos. 2013;41:668-81. In vitro assessment of drug-drug interaction potential of boceprevir associated with drug metabolizing enzymes and transporters. Chu X, Cai X, Cui D, Tang C, Ghosal A, Chan G, Green MD, Kuo Y, Liang Y, Maciolek CM, Palamanda J, Evers R, Prueksaritanont T. PubMed
  • Expert Opin Drug Metab Toxicol. 2013;9:237-52. Species differences in drug transporters and implications for translating preclinical findings to humans. Chu X, Bleasby K, Evers R. PubMed
  • J Pharmacol Toxicol Methods. 2012;65:64-74. Determining P-glycoprotein-drug interactions: evaluation of reconstituted P-glycoprotein in a liposomal system and LLC-MDR1 polarized cell monolayers. Melchior DL, Sharom FJ, Evers R, Wright GE, Chu JW, Wright SE, Chu X, Yabut J. PubMed
  • Mol Pharmacol. 2012;81:220-7. Characterization of multidrug resistance 1a/P-glycoprotein knockout rats generated by zinc finger nucleases. Chu X, Zhang Z, Yabut J, Horwitz S, Levorse J, Li XQ, Zhu L, Lederman H, Ortiga R, Strauss J, Li X, Owens KA, Dragovic J, Vogt T, Evers R, Shin MK. PubMed
  • Clin Pharmacol Ther. 2011;89:234-42. Rifampin's acute inhibitory and chronic inductive drug interactions: experimental and model-based approaches to drug-drug interaction trial design. Reitman ML, Chu X, Cai X, Yabut J, Venkatasubramanian R, Zajic S, Stone JA, Ding Y, Witter R, Gibson C, Roupe K, Evers R, Wagner JA, Stoch A. PubMed
  • Nat Rev Drug Discov. 2010;9:215-36. Membrane transporters in drug development. International Transporter Consortium, Giacomini KM, Huang SM, Tweedie DJ, Benet LZ, Brouwer KL, Chu X, Dahlin A, Evers R, Fischer V, Hillgren KM, Hoffmaster KA, Ishikawa T, Keppler D, Kim RB, Lee CA, Niemi M, Polli JW, Sugiyama Y, Swaan PW, Ware JA, Wright SH, Yee SW, Zamek-Gliszczynski MJ, Zhang L. PubMed  
  • Pharm Res. 2009;26:459-68. Metabolism and renal elimination of gaboxadol in humans: role of UDP-glucuronosyltransferases and transporters. Chu XY, Liang Y, Cai X, Cuevas-Licea K, Rippley RK, Kassahun K, Shou M, Braun MP, Doss GA, Anari MR, Evers R. PubMed
  • Mol Pharmacol. 2008;74:309-11. Role of the murine organic anion-transporting polypeptide 1b2 (Oatp1b2) in drug disposition and hepatotoxicity. Evers R, Chu XY. PubMed
  • J Pharmacol Exp Ther. 2006;317:579-89. Characterization of mice lacking the multidrug resistance protein MRP2 (ABCC2). Chu XY, Strauss JR, Mariano MA, Li J, Newton DJ, Cai X, Wang RW, Yabut J, Hartley DP, Evans DC, Evers R. PubMed
  • J Pharmacol Exp Ther. 2004;309:156-64. Transport of ethinylestradiol glucuronide and ethinylestradiol sulfate by the multidrug resistance proteins MRP1, MRP2, and MRP3. Chu XY, Huskey SE, Braun MP, Sarkadi B, Evans DC, Evers R. PubMed


New Brunswick, US

Last update: April 2021